Preliminary revenue figures for the 2024/25 financial year
Globenewswire·2025-07-01 10:46
Core Viewpoint - ChemoMetec expects to achieve revenue of approximately DKK 496 million for the financial year 2024/25, which is an increase from the previously estimated range of DKK 470-490 million [1]. Company Overview - ChemoMetec develops, manufactures, and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech, and agricultural industries globally [2]. - The company serves some of the world's leading pharmaceutical companies as its customers [2]. - ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen [3].